Estudo randomizado | Eficácia e segurança do upadacitinibe para espondilite anquilosante ativa refratária à terapia biológica.

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial – Annals of Rheumatic Diseases

Comentário no Twitter

SELECT-AXIS 2 trial – patients with #AS and inadequate response to #bDMARDs. #RCT of upadacitinb vs placebo 14 weeks:
Improved signs and symptoms of active AS and was well tolerated for 14 weeks of treatment in bDMARD-IR patients!https://t.co/Z7fuxiXMDb pic.twitter.com/kGZX9AsaVE

— ARD & RMD Open (@ARD_BMJ) July 5, 2022